usd hg coverag rate report
today pass along healthcar issuanc forecast well
updat view healthcar name coverag conjunct
broader group usd high grade coverag rate report
want commun issuanc forecast sector
includ broader group recent note avail forecast
healthcar issuanc y/i mainli driven
assumpt activ lower compar a-
relat issuanc made total healthcar issuanc
project make addit recent opportunist liability-
management-driven issuanc result low rate taken care
refinanc need margin make us believ issuanc need
lower whole healthcar compani specif subsector
issuanc estim pharma/devic gener
devic life scienc larg deriv expect
less activ compris nearli
issuanc sector healthcar issuanc came
subsector made total subsector issuanc
point estim issuanc total upjohn combin
syk-wmgi deal current account known pend
suppli healthcar servic hmo distributor servic see
issuanc next year slightli higher number issuer
healthcar servic subsector opportunist back half
term upcom matur believ lighten requir
issuanc extent off-set expect activ
return space extent follow year
 issuanc compani issuer
sector kept share repurchas activ larg within regular way cash flow
gener someth expect continu
page follow also present updat summari comment
cover compani detail individu rate view want call
attent item attach commentari first upgrad
ow view posit compani continu strong oper
perform pipelin profil post-deal view de-lever plan
achiev especi given initi debt level significantli reduc
origin expect follow dispos otezla consist
upgrad rais rate celg ow exchang get set
final upgrad rate ow given see fair
valuat well good oper conserv tone relat
balanc sheet final even remain posit aet
recent downgrad view overweight neutral given recent spread
out-performance see reason level
market balanc posit neg stori also note
posit tone
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
tabl healthcar servic recommend commentari
ci one top pick continu view esrx merger posit
 ill creat integr model posit compani ell
primari focu evidenc compani continu use
cash flow compani outlin year
plan debt repay compani ow explicit commentari
top capit deploy prioriti acceler debt repay
still see reason ci achiev de-lever goal upper
debt-to-cap year assum reason amount book valu
grow th debt-to-cap improv compani
continu de-lever progress note compani increas
share repurchas capac previous
state capac alreadi deploy total octob
though continu see compani cushion de-lever
plan look forw ard see potenti catalyst possibl sale
group benefit busi mention press report abl
recov break fee relat compani fail merger
final trial slate end novemb risk rate includ
advers court rule litig environment polit chang
leav pbm manag organ disadvantag includ
aggress balanc sheet manag expect
upgrad recommend overw eight neutral
oper fair compani continu show
conserv tone relat balanc sheet capit manag
primari support recommend someth expect
continu ith sw irl uncertainti around healthcar lab
gone radar extent see major
chang horizon spread slightli behind lh see
valu bond rel lh ell compani ithin
healthcar risk rate includ oper challeng sharehold
pressur aggress ith balanc sheet sizabl debt-
dow ngrade view aet ow follow ing recent spread
out-performance consist ith recent dow ngrade
dow ngrade recent given hat see reason
level market aetna holdco holli ow ned non-
guarante subsidiari holdco hich structur senior
holdco debt perspect aet insurance-gener cash
flow believ aet trade persist insid due
structur senior low er dollar price latest issu bond time
 maintain separ rate aet compar may
decid absorb rate time depend disclosur
made compani risk rate dow nside includ oper
setback lack focu aet ticker caus investor
prefer manag care name hile risk upsid includ
liabil manag reduc debt subsidiari level
tabl healthcar servic recommend commentari cont
recent low ere recommend credit neutral
overw eight chang view primarili reflect recent out-performance
spread hat see reason level
market opinion much perform reflect
commit credit profil despit oper setback face earli
year commit manifest june investor day comment
 ell decis includ leverag target part execut
compens formula still expect compani ill report stabl
earn go forw ard believ commit improv balanc sheet
think forw ard guidanc achiev see recent ralli spread
price fair amount improv compani credit profil
given tighten ed like see de-risk stori
return posit stanc look forw ard still expect leverag
 ill end high level
compani rate futur commit hand think
bond spread price risk potenti opioid develop
 believ leav compani subject potenti headlin risk also
see addit headlin risk disrupt regulatori oper
constant sourc nois segment hich compet
upsid dow nside risk offset view
balanc view credit
maintain neutral rate becom cautiou
current valuat given posit sentiment built surround
near-term opioid settlement even materi uncertainti still remain
addit hile recent earn seem show stabil believ
industri pressur fulli behind compani addit like mani
peer see expos drug price pressur continu
scrutini surround opioid believ event risk merit monitor
increas scrutini pharmaceut suppli chain also leav
compani suscept chang environ view like
uncertainti surround name ill hold valuat back
time ith opioid still resolv especi recent ralli
posit compani compani low er leverag peer
though see absorb ithin current valuat risk rate
upsid includ global resolut opioid litig near-term
level commensur ith compani balanc sheet spread
number year combin ith busi stabil hile risk
dow nside includ advers develop opioid reflect long-term
uncertainti risk materi higher payout
see continu opioid exposur risk maintain neutral rate
substanti recent tighten look forw ard expect opioid litig
 ill continu primari factor drive spread expect settlement
discuss ill overhang prolong period time
recent quarter also record pre-tax charg relat
opioid comment believ global settlement framew ork
agre principl ill serv basi definit settlement term
document see uncertainti settl level
compani discuss also see eakest posit
distributor head possibl settlement given recent spread
tighten see risk adequ price oper setback
convers chang pharma suppli chain add doubt
futur ell post larg acquisit compani cushion
current rate continu diminish posit note
compani commit repay least debt next year
expect futur capit deploy ill disciplin risk
dow nside rate includ eak drug price trend chang
model leav distributor disadvantag advers opioid
develop hile risk upsid includ potenti turnaround
price trend could substanti boost profit balanc sheet
conservat near-term favor resolut opioid liabil
tabl healthcar servic recommend commentari cont
laboratori corp
hold neutral rate amidst chang environ
compani oper result strong
 ith compani show ing stabil medic loss ratio adjust
medicar advantag membership forecast upw ard futur
sector uncertain manag express desir maintain
financi strateg flexibl continu evalu strateg acquisit
build capabl particularli primari care result despit
strong oper perform strong posit medicar
advantag see event risk higher compar peer go forw ard
key item monitor risk rate upsid includ sustain
oper perform conjunct ith conserv balanc sheet
manag market revisit possibl full acquisit
higher-r peer hile risk dow nside includ pursuit larg
debt-financ continu uncertaini regard move
tow ard democrat primari debat
hold lh neutral out-performance vs closest peer long-end
bond move back earlier year flat
current rate driven fact much posit name
de-lever post covanc get high end leverag target
envigo financ conserv ell fli radar
midst recent servic subsector uncertainti price point
oper trend good enough credit recent
see big next month compani plan much
prospect debt reduct believ event risk ill persist part
stori time risk dow nside includ aggress
 ith compani say ould continu look attract tuck-in
opportun given balanc sheet strength favor debt matur
schedul ell sector disrupt leav independ lab
disadvantag risk upsid includ conserv balanc sheet
manag expect strong oper perform
continu face concern opioid epidem settl tw
ohio counti recent engag discuss broader settlement
similar distributor see market much optim
someth believ ill take time resolv pass
uncertainti addit oper headw ind persist amid brand
gener drug price trend expect margin headw ind
europ ill take time turn around look forw ard expect ill
stay import part healthcar suppli chain see uncertainti
busi risk limit spread out-performance time despit
on-going litig continu open
balanc valuat expect altern return capit risk
rate includ posit turnaround environ financi
conservat expect near-term resolut potenti opioid
liabil hile neg risk includ acceler industri competit
continu eak price environ healthcar reform
advers affect distributor potenti larg opioid
settlement market expect ould neg affect balanc
tabl healthcar servic recommend commentari cont
see best posit compani manag space
 view compani diversif unregul cash flow strong
credit posit firm diversifi ithin medic benefit
busi it strong result optum servic
offer addit hile compani debt-to-capit stand high-
zone strong cash flow capit grow th enabl
delev faster peer note higher leverag metric
less issu rel peer given larg servic busi
 comfort ith exposur compani overal
diversifi busi model appear insul headlin sw irl
around greater manag space current valuat ell insid
peer hold us back posit view nside risk
rate includ slow ed pace de-lever ell oper setback
core insur servic busi nois given on-going
industri debat pharma suppli chain convers risk
upsid includ strong result across busi line addit
maintain uw rate still feel current level tight
rel peer given compani profil concern potenti
event risk given potenti regulatori overhang though past
month becom less cautiou valuat
under-perform peer ci hole rate inform
uncertain manag environ high leverag debt-to-capit
end end quarter open potenti risk
outstand ci litig remain focus tuck-in
said take anyth tabl point time
 ill react market condit accordingli hile expect ill
eventu pay break fee ci note
upsid potenti court rule favor demand payment
everyth taken togeth pair ith valuat still tight
peer believ level ill under-perform believ ci trade
insid time risk rate includ potenti shift tow ard
conserv financi polici improv oper perform ell
posit develop relat
tabl pharma/med devic recommend commentari
upgrad recommend ow
strong oper pipelin profil post deal ill off-set elev debt
level see compani de-lever plan achiev see
compani commit reduc debt especi given initi debt level
combin compani ill significantli reduc follow ing dispos
otezla ith compani say proce sale ill
priorit reduc near-term debt avoid excess initi leverag
compani addit comment de-lever roadmap say
exit expect leverag ay
 believ de-lever de-risk stori advanc revlimid
lose patent protect medium term believ compani
compress peer make de-lever progress long
opdivo maintain good posit advers
develop revlimid patent situat time expect
compani ill conserv peer risk rate includ
chang manag disposit tow ard financi polici debt paydow
pace slow er anticip larger scale pipelin failur advers
consist ith upgrad today rais rate celg
ow note ever transact close
near-term plan remov separ credit rate celg given
substanti major old celg debt ill box
structur legaci debt per term
exchang risk rate dow nside includ transact
recent spread under-perform left us littl posit bias
credit neutral view remain essenc fair spread level
solid recent oper result off-set open focu continu futur
 percept market higher event risk like hold
spread back time still comfort ith credit note
compani consist paid dow debt sinc tax reform gave
access global cash flow hile issu debt time
either kept share repurchas dividend line ith free cash
flow follow ing acquisit otezla stake beigen
cash balanc ill declin see tw transact rel
low -risk credit perspect expect debt issuanc
base compani comment follow ing deal note
capit alloc prioriti remain intact state ill continu
invest grow th busi intern extern
time ill atch comment incom cfo ell
high proport matur drug ithin portfolio above-averag risk
increas biosimilar adopt come year risk rate
includ potenti substanti debt-fund convers balanc
sheet conservat could lead de-lever slow er pace
tabl pharma/med devic recommend commentari cont
co
continu rate neutral ith tight valuat offset continu
posit view credit belief ill upgrad rate
back ig near-term view may bp tighten
 hen upgrad happen part see price
gross leverag end recent quarter compani
calcul basi initi leverag bcr transact
rang dow end also note manag
consist reaffirm expect delev
decemb ith compani note recent quarter
leverag target commit rate agenc though think
come target expect float mid-to-low time
comment could indic compani talk
agenc could foreshadow upgrad view capit
alloc compani said look cash flow
 ill look specif tuck-in ad interest
anoth larg deal see lot opportun expand recent
limit activ time expect compani ill activ
hold recommend back somew hat risk rate
dow nside includ busi setback could lead oper pressur
exposur market beta sentiment risk upsid includ
potenti compani pursu divestitur alter financ plan
accordingli improv rate sooner expect
maintain recommend neutral compani
elev debt level part fund loxo deal
upcom loe sever major product expect ill
modestli size base recent commentari expect sharehold return
 ill ithin cash flow risk upsid rate includ acceler
repay debt hile risk dow nside includ less conserv
financi polici addit opportun compani ork
maintain recommend neutral given manag
busi uncertainti make us feel spread ill perform line ith
market certainti achiev histor felt market
 price much risk larg given larg cash balanc
disciplin manag team new ceo ith new prioriti
transit cfo leav us less comfort look forw ard note
compani said approach extern partnership
 ill much hat saw past ill driven
scienc hich larg consist ith statu quo someth
view continu support credit addit hile note
debt repay drop initi statement capit
deploy prioriti compani continu repay debt
year ytd issu market sinc still see
larg cash balanc substanti posit insul factor
event risk expect market give credit
past risk upsid includ conserv balanc sheet
manag expect ith compani continu hold larg
amount cash balanc sheet risk dow nside includ
chang financi polici potenti larger acquisit lead
rate pressur given busi trend diminish cushion
current rate ell neg develop relat truvada patent
law suit ith govern
tabl pharma/med devic recommend commentari cont
maintain neutral rate given keytruda continu
success stabl oper therapeut categori valuat
tight end compani peer set current see
valuat fair hen consid posit neg compar
mani peer manag continu de-emphas large-scal
focus deal believ value-ad ith minimum
disrupt on-going scientif effort light see risk
larg debt-financ acquisit low compar other space
risk upsid includ addit posit pipelin result along ith
limit deal make strengthen compani alreadi high-qual balanc
sheet flight qualiti event market sell-off hile risk
dow nside includ larg debt-financ signific financi polici
maintain neutral post agreement merg compani ith
upjohn unit view develop significantli posit
credit stori especi given remov strateg review uncertain
overhang sinc august form larger industri
player ith stabl cash flow stronger balanc sheet
addtion view chang manag much team
remov netherland sticht structur initi credit friendli
commentari ith commit invest grade rate leverag
substanti posit time posit
bias stori believ combin compani trade closer
rest healthcar peer ig though expect ill take time
develop particular perspect need see progress tow ard
regulatori approv order get posit reduc
leverag compani continu expect reach
debt repay target risk upsid includ myl-upjohn
deal close ith combin compani manag balanc sheet
conserv trend chines market stabil hile risk
dow nside includ deal fall apart unanticip neg chines drug
price dynam ell neg develop relat
valuat remain ide maintain neutral rate
see signific near-term execut risk remain relat seper
rx busi last quarter compani state ould need
evalu time seper due uncertainti market
gener pharmaceut industri provid updat quarter
also see busi oper challeng persist recent
need time on-going tax issu potenti enorm hen
compar size compani compani also disclos
receiv draft nopa ir relat deduct interest
debt ow ed incur connect ith merger
 hich note third distinct tax disput compani face
said even though view rate safe
agenc incorpor tax uncertainti rate
compani reiter commit debt paydow invest
grade rate say ant leverag eventu mani
neg uncertainti stori like keep spread ide
level near term see show stori ill
need prove bond outperform risk rate
dow nside includ potenti eak oper result abandon rx
separ eaken compani ig commit aggress
 risk upsid includ potenti better oper result
continu basi conserv balanc sheet manag use
substanti proce rx sale tow ard debt reduct ell
quick resolut ith irish tax author ir
tabl pharma/med devic recommend commentari cont
hold neutral rate given recent solid oper result
organ grow th strong ell on-going de-lever off-set
tight valut potenti near-term risk compani
made signific progress de-lever ith leverag end
quarter dow end compani reduc debt
driven strong ytd cash flow gener compani
expect debt level though allow
focu activ ith compani say substanti
capac acquisit activ funnel feel great
 hat pipelin look like recent media report suggest
compani may look current ev hich hile
think ould consist ith compani prior stratey ould like
met ith initi iden ever compani track record give
investor level confid ould see iden
buy opportun given financ deal past show
consist de-lever risk upsid includ balanc sheet
conservat rapid de-lever expect dow nside
realiz concern greater lever activ via oper
continu hold neutral rate given steadi oper
perform fair balanc sheet off-set current valuat
believ appropri reflect dynam current sit tight end
fair valu also expect rate ill stay leverag
 ill remain zone guid manag view
firm oper posit thank lead posit credit-friendli
anim health industri consist oper result last
year also note ill transit ceo begin next year
 ith kristin peck current evp presid us oper slate
take risk dow nside includ potenti firm
significantli increas leverag fund major transact though note
abil pursu large-scal deal sector limit anti-trust concern
market share manag indic desir pursu
risk upsid includ continu oper strength conserv
compani state past plan lever balanc sheet
time net leverag someth ould requir signific
increment debt current level ever signific time pass
 ithout dramat action net leverag current sit slightli
posit expect remain risk
someth expect compani ill pursu time compani
time indic look larg deal time indic
prefer smaller deal view like present persist
risk caus spread trade ide investor feel resolut
reach addit note compani inform us
sec intern investig intra-compani transact undertaken
purpos gener fx gain loss date back least
 ith investig earli stage hich view uncertainti
overhang go forw ard ould need see posit resolut
investig includ becom current financi order take
posit stanc compani risk rate includ mute
pace balanc sheet re-lev continu prefer
market devic name healthcar sector
tabl pharma/med devic recommend commentari cont
remain underw eight follow ing posit develop
aducanumab view come tight valuat compar
peer persist threat lack product
diversif ell compani limit debt footprint capac
leverag increas relat aducanumab materi uncertanti still
remain view includ hether fda ill ultim approv
submiss though believ recent develop low er
probabl compani feel need execut materi
near-term believ oper result remain fair leverag
remain low also concern compani relianc ms
drug futur event risk overal regulatori environ biotech
compani go forw ard base comment compani ultim
 expect ill emerg lever higher risk compani
perceiv today risk rate includ near-term approv
aducanumab conserv balanc sheet manag
view one strongest compani sector ith
substanti diversif across consum medic devic pharma
market ever compani trade tight level present
limit upsid view addit talc litig repres
unpredict risk ill like take extend period time play
compani also involv signific opioid litig hich like
consistenli eigh sentiment settl ith tw ohio counti track
one mdl recent book larg charg connect ith
propos global settlement discuss ith four state ag
focus compani remain open acquisit
specif medic devic busi addit
place compani aaa rate review dow ngrade
believ litig overhang could pressur rate time long
term expect compani ill face increas call split lever
time expect ill gain much traction risk
rate includ potenti firm undertak signific debt reduct
degre resolut litig near-term
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect research analyst person view subject secur issuer
part research analyst compens directli indirectli relat specif recommend
view express research analyst report korea-bas research analyst list front cover applic
also certifi per kofia requir analysi made good faith view reflect opinion
without undu influenc intervent
author name within report research analyst unless otherwis specifi europ sector specialist may shown
report contact author report part research depart
